WESTON, Fla
Obvius Robotics, Inc., a medical device company that has developed an innovative technology platform for performing percutaneous access, today announced the successful completion of its first human cases.
We know that early central venous catheter insertion yields the best results in reducing mortality and hospitalization in acutely ill ICU and ER patients, stated William Cohn, MD, Chief Medical Officer of Obvius Robotics and inventor of the CERTA Access System. CERTA enables clinicians of various levels of experience to quickly and reliably treat these patients, and in so doing, democratizes and standardizes a common procedure that today requires a certain level of skill and experience.
The Obvius Robotics CERTA Access System is a development stage device that enables clinicians to single-handedly target anatomical structures and access them with the push of a button using a proprietary targeting system and needle assembly. While the product is not yet available for sale, the company is preparing for regulatory clearance and commercialization.
This successful first-in-human study comes after two years of rigorous work proving the design and value proposition in a preclinical setting, stated Russell Seiber, CEO and President of Obvius Robotics. We hope this will mark an important milestone in bringing this potentially groundbreaking technology to patients on a global scale.
Disclaimer: This story was supplied by an external content provider; we do not endorse or accept responsibility for its accuracy, completeness, or any outcomes from relying on it. It is for informational purposes only and does not constitute legal, financial, medical, or other professional advice. Laws and regulations vary and may change; readers should verify accuracy and compliance with local requirements and consult a qualified professional for tailored guidance.